Search

Your search keyword '"Nechaeva, Marina"' showing total 126 results
Start Over Author "Nechaeva, Marina"
126 results on '"Nechaeva, Marina"'

1. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Author

Baramidze, Ana, Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, AG McIntyre, Debra, Perez, Javier, Kaul, Manika, Quek, Ruben G.W., Seebach, Frank, Rietschel, Petra, and Pouliot, Jean-Francois

Published
2024
Full Text
View/download PDF

4. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Author

Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Duc, Anh Nguyen, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, and Schmid, Peter

Subjects
Clinical Trials and Supportive Activities, Cancer, Clinical Research, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Albumins, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Humans, Lymphocytes, Tumor-Infiltrating, Paclitaxel, Triple Negative Breast Neoplasms, Tumor Microenvironment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundUnderstanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel (A+nP) vs placebo and nP in unresectable (P+nP) locally advanced or metastatic triple-negative breast cancer.MethodsPatients were randomly assigned 1:1 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) and atezolizumab 840 mg every 2 weeks or placebo until progression or toxicity. Progression-free survival and overall survival were evaluated based on programmed death-ligand 1 (PD-L1) expression on immune cells (IC) and tumor cells, intratumoral CD8, stromal tumor-infiltrating lymphocytes, and BRCA1/2 mutations.ResultsPD-L1 IC+ in either primary or metastatic tumor tissue was linked to progression-free survival and overall survival benefit with A+nP. PD-L1 IC+ low (26.9%; 243 of 902 patients) and high (13.9%; 125 of 902 patients) populations had improved outcomes that were comparable. Intratumoral CD8 and stromal tumor-infiltrating lymphocytes positivity (sTIL+) were associated with PD-L1 IC+ status; improved outcomes were observed with A+nP vs P+nP only in CD8+ and sTIL+ patients who were also PD-L1 IC+. BRCA1/2 mutations (occurring in 14.5% [89 of 612 patients]) were not associated with PD-L1 IC status, and PD-L1 IC+ patients benefited from A+nP regardless of BRCA1/2 mutation status.ConclusionsAlthough A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.

Published
2021

5. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Author

Moehler, Markus, Dvorkin, Mikhail, Boku, Narikazu, Özgüroğlu, Mustafa, Ryu, Min-Hee, Muntean, Alina S, Lonardi, Sara, Nechaeva, Marina, Bragagnoli, Arinilda C, Coşkun, Hasan S, Gracian, Antonio Cubillo, Takano, Toshimi, Wong, Rachel, Safran, Howard, Vaccaro, Gina M, Wainberg, Zev A, Silver, Matthew R, Xiong, Huiling, Hong, Janet, Taieb, Julien, and Bang, Yung-Jue

Subjects
Rare Diseases, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Female, Fluorouracil, Follow-Up Studies, Humans, Induction Chemotherapy, Maintenance Chemotherapy, Male, Middle Aged, Oxaliplatin, Prognosis, Stomach Neoplasms, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti-programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC.Patients and methodsJAVELIN Gastric 100 was a global, open-label, phase III trial. Eligible patients had untreated, unresectable, human epidermal growth factor receptor 2-negative, locally advanced or metastatic GC or GEJC. Patients without progressive disease after 12 weeks of first-line chemotherapy with oxaliplatin plus a fluoropyrimidine were randomly assigned 1:1 to avelumab 10 mg/kg every 2 weeks or continued chemotherapy, stratified by region (Asia v non-Asia). The primary end point was overall survival (OS) after induction chemotherapy in all randomly assigned patients or the PD-L1-positive randomly assigned population (≥ 1% of tumor cells; 73-10 assay).ResultsA total of 805 patients received induction; 499 were randomly assigned to avelumab (n = 249) or continued chemotherapy (n = 250). Median OS was 10.4 months (95% CI, 9.1 to 12.0 months) versus 10.9 months (95% CI, 9.6 to 12.4 months) and 24-month OS rate was 22.1% versus 15.5% with avelumab versus chemotherapy, respectively (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .1779). In the PD-L1-positive population (n = 54), the HR for OS was 1.13 (95% CI, 0.57 to 2.23; P = .6352). In an exploratory analysis of the PD-L1-positive population, defined as combined positive score ≥ 1 (22C3 assay; n = 137), median OS was 14.9 months (95% CI, 8.7 to 17.3 months) with avelumab versus 11.6 months (95% CI, 8.4 to 12.6 months) with chemotherapy (unstratified HR, 0.72; 95% CI, 0.49 to 1.05). With avelumab and chemotherapy, treatment-related adverse events (TRAEs) occurred in 149 (61.3%) and 184 (77.3%) patients, including grade ≥ 3 TRAEs in 31 (12.8%) and 78 (32.8%) patients, respectively.ConclusionJAVELIN Gastric 100 did not demonstrate superior OS with avelumab maintenance versus continued chemotherapy in patients with advanced GC or GEJC overall or in a prespecified PD-L1-positive population.

Published
2021

6. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Author

Qin, Shukui, Chan, Stephen L, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Zhang, Mingxiang, Xu, Li, Yuan, Xianglin, Li, Da, Ying, Jierer, Zhang, Jingdong, Zhang, Tao, Gu, Kangsheng, He, Yifu, Hao, Ping, Jiang, Da, Zhang, Shu, Xing, Baocai, Zhang, Baihong, Wang, Dong, Zhai, Xiaofeng, Liang, Houjie, Cybulska-Stopa, Bozena, Dvorkin, Mikhail, Stroyakovskiy, Daniil, Nechaeva, Marina, Yen, Chia-Jui, Su, Wei-Wen, Chen, Yen-Hao, Bondarenko, Igor, Yang, Lin, Fang, Weijia, Gomez-Martin, Carlos, Ryu, Min-Hee, Kim, Han-Sang, Kim, Jee-Hyun, Zarubenkov, Oleg, Orlova, Rashida, Poddubskaya, Elena, Fadeeva, Natalia, Makarova, Yulia, Chao, Yee, Hung, Chao-Hung, Neffa, Maryna, Vynnychenko, Oleksandr, Burgoyne, Adam, Hao, Chunyi, Mohr, Raphael U, Diaz-Beveridge, Roberto, Feliu-Batlle, Jaime, Cubillo-Gracian, Antonio, Lee, Ann-Shing, Daniele, Bruno, Antonuzzo, Lorenzo, Sangiovanni, Angelo, Gasbarrini, Antonio, Scartozzi, Mario, Ahn, Mi Sun, Oh, Sung-Yong, Orlov, Sergey, Harputluoglu, Hakan, Oksuzoglu, Berna, Hsu, Chiun, Rau, Kun-Ming, Krechkovskyi, Oleksandr, Yareshko, Vladimir, Xiong, Henry, Lee, Fa-Chyi, Jiang, Yixing, Gabayan, Afshin, Crow, Mary, Van Steenkiste, Christophe, and Verset, Gontran

Published
2023
Full Text
View/download PDF

7. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Author

Özgüroğlu, Mustafa, Kilickap, Saadettin, Sezer, Ahmet, Gümüş, Mahmut, Bondarenko, Igor, Gogishvili, Miranda, Nechaeva, Marina, Schenker, Michael, Cicin, Irfan, Ho, Gwo Fuang, Kulyaba, Yaroslav, Zyuhal, Kasimova, Scheusan, Roxana-Ioana, Garassino, Marina Chiara, He, Xuanyao, Kaul, Manika, Okoye, Emmanuel, Li, Yuntong, Li, Siyu, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, and Rietschel, Petra

Published
2023
Full Text
View/download PDF

8. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Author

Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Baramidze, Ana, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Li, Siyu, Li, Yuntong, Kaul, Manika, Quek, Ruben G.W., Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, and Rietschel, Petra

Published
2023
Full Text
View/download PDF

9. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Author

Gogishvili, Miranda, Melkadze, Tamar, Makharadze, Tamta, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno-Jaime, Brizio, Passalacqua, Rodolfo, Li, Siyu, McGuire, Kristina, Kaul, Manika, Paccaly, Anne, Quek, Ruben G. W., Gao, Bo, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Gullo, Giuseppe, and Rietschel, Petra

Published
2022
Full Text
View/download PDF

10. Ecological approaches to the formation of sustainable rural development

Author

Nechaeva Marina, Kuklin Andrey, Demidova Elena, Mottaeva Asiiat, and Pryadko Igor

Subjects
Environmental sciences, GE1-350
Abstract

The article deals with the features of the functioning and development of rural areas as the basis for the formation of social infrastructure in the educational field. The author studies basic problems and the state of the program for the development of rural areas, analyzes indicators of socio-economic development, creates a program of social infrastructure in the framework of the development of the national project “Education”, applies the method of forecasting key indicators. Moreover, the author studies the features of developing rural areas analyzing key cost parameters; develops approaches to predicting changes in key cost indicators for the maintenance of preschool and educational institutions; considers the relationship of the most significant factors of their functioning. Due to a quantitative assessment of structural changes, the forecast values of costs for future periods have been revealed. It has been established that the resulting method can optimally organize the development process of an organization, thanks to a well-thought-out algorithm for calculating predicted values, and can be used for any organization in the social and cultural sphere. The author makes conclusions about prospects for developing rural areas in the context of the development program. The proposed action plan for managing costs in terms of maintaining social infrastructure facilities contributes to optimizing the process of making managerial decisions, takes into account relevant costs, simplifies the choice of the preferred option for solving the problem.

Published
2024
Full Text
View/download PDF

11. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Author

Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, and Oza, Amit M

Published
2022
Full Text
View/download PDF

12. Classification of Rural Areas Based on a Comprehensive Assessment of Their Development

Author

Frolova, Olga A., Shamin, Anatolii E., Shkilev, Nikolay P., Nechaeva, Marina L., Bolshakova, Ulia A., Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, and Bogoviz, Aleksei V., editor

Published
2021
Full Text
View/download PDF

16. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

17. Influence of solar activity and geographic latitude on genetic homeostasis of human somatic cells.

Author

Kalaev, Vladislav N, primary, Zuevsky, Vladislav P, additional, Nechaeva, Marina S, additional, Ilyinskikh, Nikolay N, additional, Ilyinskikh, Ekaterina N, additional, Lantushenko, Anastasiya O, additional, Korneeva, Olga S, additional, Zuevskaya, Tatiana V, additional, Larina, Anna V, additional, Shipilova, Evgeniya N, additional, Gavrilova, Valentina A, additional, Baranov, Denis Yu, additional, and Degtyar (Skuratovskaya), Irina V, additional

Published
2023
Full Text
View/download PDF

21. Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Author

Makharadze, Tamta, primary, Quek, Ruben G. W., additional, Melkadze, Tamar, additional, Gogishvili, Miranda, additional, Ivanescu, Cristina, additional, Giorgadze, Davit, additional, Dvorkin, Mikhail, additional, Penkov, Konstantin, additional, Laktionov, Konstantin, additional, Nemsadze, Gia, additional, Nechaeva, Marina, additional, Rozhkova, Irina, additional, Kalinka, Ewa, additional, Gessner, Christian, additional, Moreno‐Jaime, Brizio, additional, Passalacqua, Rodolfo, additional, Konidaris, Gerasimos, additional, Rietschel, Petra, additional, and Gullo, Giuseppe, additional

Published
2023
Full Text
View/download PDF

22. The concept of sustainable development of territories

Author

Mottaeva Angela, Nechaeva Marina, and Nechaev Vladimir

Subjects
Environmental sciences, GE1-350
Abstract

The authors of the article study the features of functioning and development of territories as the bases of forming of social infrastructure in the education sphere. The basic problems and the condition of the programme of the territories development are considered, the indicators of social-and-economic development are analyzed, the procedures of the programme creation for the development of social infrastructure within the development of the national Education project, the technique of forecasting of key indicators is applied. The features of the territories development with carrying out the analysis of the key parameters are investigated. The need of the programme of the social infrastructure development regarding education during of identification, studying micro- and macro-factors of the development of the area is proved. The approaches to the realization of the stages of the development programme and forecasting of change of key indicators are developed, the interrelation of the most important factors of their functioning is investigated. The periods in which there were maximum structural changes in development of rural territories are revealed as the result of quantitative assessment of structural shifts. It is proved that this approach is the tool allowing to improve the process of social-and-economic development taking into account the forecast, and, therefore, to increase the efficiency of activity of the sphere of education that will allow to strengthen the financial state and positions of the enterprises of this industry in the market. Some conclusions are drawn on the prospects of the territories development in the conditions of development and implementation of the development programme.

Published
2021
Full Text
View/download PDF

23. ≪Deprive of Monasticism and... Send... to the Places of Previous Dwellings≫

Author

Nechaeva Marina

Subjects
Russian Orthodox Church, monasteries, monasticism, secularization, the church and the state, the investigation files, the synodal period, History of Russia. Soviet Union. Former Soviet Republics, DK1-4735, History and principles of religions, BL660-2680
Abstract

The article deals with the legal framework and practice of investigation in the cases of monks’ vows performed in 1730s following the prohibitive edicts of 1720s. The research showed that the restrictive standards regarding age, education and social attitude, fundamentally contradicted the existing traditions of formation of Orthodox monasticism in Russia. This was the main reason for their mass non-fulfi lment. Only the investigations performed in 1730s and the subsequent harsh measures of defrocking, fining, public punishment and exiles along with the established mechanism for reporting and control of the vows made monasteries to fulfill the edicts. The implementation of restrictions on the monks’ vows led to a sharp reduction in the number of monks and put monasteries on the brink of survival. Thus, the investigations of 1730s became a fundamentally important milestone in the implementation of the secularization reform of Russian Orthodox monasteries.

Published
2016
Full Text
View/download PDF

24. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Author

Al-Samkari, Hanny, primary, Geredeli, Caglayan, additional, Arslan, Cagatay, additional, Korantzis, Ippokratis, additional, Dogu, Gamze Gokoz, additional, Nechaeva, Marina, additional, Fernandez, Mercedes Salgado, additional, Astorga, Beatriz Gonzalez, additional, Yordanov, Valeriy, additional, Ciuleanu, Tudor-eliade, additional, Bowers, Charles, additional, Armas, Armando, additional, Scotte, Florian, additional, Camargo, Johnny, additional, Muñoz, César, additional, Bunn, Paul, additional, Kuter, David J., additional, and Soff, Gerald A., additional

Published
2022
Full Text
View/download PDF

28. Lingua e identità nel contesto dell'emigrazione dal Canton Ticino verso la Russia dal Settecento fino alla Rivoluzione d'ottobre

Author

Nechaeva, Marina and Nechaeva, Marina

Abstract

La presente tesi di dottorato verte sul legame tra lingua e identità e studia il mantenimento della lingua patrimoniale nel contesto dell'emigrazione dal Canton Ticino verso la Russia dal Settecento alla Rivoluzione d'Ottobre. L'analisi empirica si basa su un corpus di riferimento costituito da più di quattrocentocinquanta documenti di carattere epistolare e memorialistico raccolto presso diversi archivi di stato e privati in Russia e in Svizzera. La tesi è articolata in tre capitoli, introdotti da una parte isagogica in cui viene definito il quadro dottrinale che funge da base teorica per l'analisi del corpus. La parte introduttiva delinea inoltre la metodologia utilizzata per l'indagine empirica e descrive il lavoro di ricerca svolto negli archivi per la raccolta dei dati empirci e la selezione del campione. Il primo capitolo studia le possibili cause che hanno spinto generazioni di ticinesi ad emigrare in Russia nel periodo indicato. Partendo dal presupposto che l'emigrazione coinvolge sia dinamiche nella società di origine che in quella d'approdo, ho presentato un quadro il più possibile esaustivo sui principali fattori di spinta e di attrazione che hanno alimentato l'emigrazione dal Canton Ticino verso la Russia. Inoltre, al fine di spiegare la particolare trama identitaria dei ticinesi, nel primo capitolo ho affrontato e descritto in chiave storica il particolare processo di formazione del Canton Ticino. Il mantenimento della lingua patrimoniale, per sua definizione, si riferisce a circostanze che sembrerebbero favorirne il logoramento. Pertanto, il presente studio esamina un contesto d'emigrazione e di confronto con una realtà linguistica e culturale distinta dall'abituale, dove l'identità e soprattutto la lingua sono soggette a continue sollecitazioni e tensioni. La prima parte del secondo capitolo si occupa della ricognizione e della descrizione dei cambiamenti dovuti al contatto linguistico della lingua degli emigrati ticinesi in Russia. Partendo dal corpu

Published
2022

29. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Author

Kristeleit, R, Lisyanskaya, A, Fedenko, A, Dvorkin, M, de Melo, A, Shparyk, Y, Rakhmatullina, I, Bondarenko, I, Colombo, N, Svintsitskiy, V, Biela, L, Nechaeva, M, Lorusso, D, Scambia, G, Cibula, D, Póka, R, Oaknin, A, Safra, T, Mackowiak-Matejczyk, B, Ma, L, Thomas, D, Lin, K, Mclachlan, K, Goble, S, Oza, A, Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M, Kristeleit, R, Lisyanskaya, A, Fedenko, A, Dvorkin, M, de Melo, A, Shparyk, Y, Rakhmatullina, I, Bondarenko, I, Colombo, N, Svintsitskiy, V, Biela, L, Nechaeva, M, Lorusso, D, Scambia, G, Cibula, D, Póka, R, Oaknin, A, Safra, T, Mackowiak-Matejczyk, B, Ma, L, Thomas, D, Lin, K, Mclachlan, K, Goble, S, Oza, A, Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, and Oza, Amit M

Abstract

Background: Few prospective studies have compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or BRCA2-mutated ovarian carcinoma. We aimed to assess rucaparib versus platinum-based and non-platinum-based chemotherapy in this setting. Methods: In this open-label, randomised, controlled, phase 3 study (ARIEL4), conducted in 64 hospitals and cancer centres across 12 countries (Brazil, Canada, Czech Republic, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, the UK, and the USA), we recruited patients aged 18 years and older with BRCA1-mutated or BRCA2-mutated ovarian carcinoma, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had received two or more previous chemotherapy regimens. Eligible patients were randomly assigned (2:1), using an interactive response technology and block randomisation (block size of six) and stratified by progression-free interval after the most recent platinum-containing therapy, to oral rucaparib (600 mg twice daily) or chemotherapy (administered per institutional guidelines). Patients assigned to the chemotherapy group with platinum-resistant or partially platinum-sensitive disease were given paclitaxel (starting dose 60–80 mg/m2 on days 1, 8, and 15); those with fully platinum-sensitive disease received platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy). Patients were treated in 21-day or 28-day cycles. The primary endpoint was investigator-assessed progression-free survival, assessed in the efficacy population (all randomly assigned patients with deleterious BRCA1 or BRCA2 mutations without reversion mutations), and then in the intention-to-treat population (all randomly assigned patients). Safety was assessed in all patients who received at least one dose of assigned study treatment. This study is registered with ClinicalTrials.gov, NCT02855944; enrolment is complete, and the study

Published
2022

31. 1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study

Author

Kristeleit, Rebecca, primary, Lisyanskaya, Alla, additional, Fedenko, Alexander, additional, Dvorkin, Mikhail, additional, de Melo, Andreia Cristina, additional, Shparyk, Yaroslav, additional, Rakhmatullina, Irina, additional, Bondarenko, Igor, additional, Colombo, Nicoletta, additional, Svintsitskiy, Valentyn, additional, Biela, Luciano, additional, Nechaeva, Marina, additional, Raspagliesi, Francesco, additional, Scambia, Giovanni, additional, Cibula, David, additional, Póka, Róbert, additional, Oaknin, Ana, additional, Safra, Tamar, additional, Mackowiak-Matejczyk, Beata, additional, Ma, Ling, additional, Thomas, Daleen, additional, Lin, Kevin, additional, McLachlan, Karen, additional, Goble, Sandra, additional, and Oza, Amit, additional

Published
2021
Full Text
View/download PDF

32. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice

Author

Tjulandin, Sergey, primary, Demidov, Lev, additional, Moiseyenko, Vladimir, additional, Protsenko, Svetlana, additional, Semiglazova, Tatiana, additional, Odintsova, Svetlana, additional, Zukov, Ruslan, additional, Lazarev, Sergey, additional, Makarova, Yuliya, additional, Nechaeva, Marina, additional, Sakaeva, Dina, additional, Andreev, Aleksey, additional, Tarasova, Anna, additional, Fadeyeva, Natalya, additional, Shustova, Mariia, additional, and Kuryshev, Ivan, additional

Published
2021
Full Text
View/download PDF

33. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Author

Sezer, Ahmet, primary, Kilickap, Saadettin, additional, Gümüş, Mahmut, additional, Bondarenko, Igor, additional, Özgüroğlu, Mustafa, additional, Gogishvili, Miranda, additional, Turk, Haci M, additional, Cicin, Irfan, additional, Bentsion, Dmitry, additional, Gladkov, Oleg, additional, Clingan, Philip, additional, Sriuranpong, Virote, additional, Rizvi, Naiyer, additional, Gao, Bo, additional, Li, Siyu, additional, Lee, Sue, additional, McGuire, Kristina, additional, Chen, Chieh-I, additional, Makharadze, Tamta, additional, Paydas, Semra, additional, Nechaeva, Marina, additional, Seebach, Frank, additional, Weinreich, David M, additional, Yancopoulos, George D, additional, Gullo, Giuseppe, additional, Lowy, Israel, additional, and Rietschel, Petra, additional

Published
2021
Full Text
View/download PDF

34. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Author

Emens, Leisha A, primary, Molinero, Luciana, additional, Loi, Sherene, additional, Rugo, Hope S, additional, Schneeweiss, Andreas, additional, Diéras, Véronique, additional, Iwata, Hiroji, additional, Barrios, Carlos H, additional, Nechaeva, Marina, additional, Nguyen-Duc, Anh, additional, Chui, Stephen Y, additional, Husain, Amreen, additional, Winer, Eric P, additional, Adams, Sylvia, additional, and Schmid, Peter, additional

Published
2021
Full Text
View/download PDF

36. A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).

Author

Schmid, Peter, primary, Cortes, Javier, additional, Robson, Mark E., additional, Iwata, Hiroji, additional, Hegg, Roberto, additional, Nechaeva, Marina, additional, Xu, Binghe, additional, Verma, Sunil, additional, Haddad, Vincent, additional, Rodrigo Imedio, Esteban, additional, Schiavon, Gaia, additional, Foxley, Andrew, additional, and Park, Yeon Hee, additional

Published
2020
Full Text
View/download PDF

37. Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

Author

Schmid, Peter, primary, Cortes, Javier, additional, Robson, Mark, additional, Iwata, Hiroji, additional, Hegg, Roberto, additional, Verma, Sunil, additional, Nechaeva, Marina, additional, Xu, Binghe, additional, Haddad, Vincent, additional, Imedio, Esteban Rodrigo, additional, Schiavon, Gaia, additional, Foxley, Andrew, additional, and Park, Yeon Hee, additional

Published
2020
Full Text
View/download PDF

38. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Author

Moehler, Markus H., primary, Dvorkin, Mikhail, additional, Ozguroglu, Mustafa, additional, Ryu, Min-hee, additional, Muntean, Alina Simona, additional, Lonardi, Sara, additional, Nechaeva, Marina, additional, Campos Bragagnoli, Arinilda Silva, additional, Coskun, Hasan Senol, additional, Cubillo Gracián, Antonio, additional, Takano, Toshimi, additional, Wong, Rachel, additional, Safran, Howard, additional, Vaccaro, Gina M., additional, Boku, Narikazu, additional, Conti, Ilaria, additional, Hong, Janet, additional, Xiong, Huiling, additional, Taieb, Julien, additional, and Bang, Yung-Jue, additional

Published
2020
Full Text
View/download PDF

40. Совершенствование управления базовыми станциями операторов мобильной связи в условиях рынка

Author

Nechaeva, Marina

Subjects
экономико-математическое моделирование, прогнозирование, технико-экономическое обоснование, инфраструктура операторов мобильной связи, forecasting, economic-mathematical modeling, feasibility analysis, market of mobile communication, рынок мобильной связи, infrastructure of mobile operators
Abstract

Формирование рынка телекоммуникационных технологий в России характеризуется некоторым отставанием от развитых стран, в связи с этим анализ отечественного рынка мобильной связи становится крайне приоритетным направлением в рамках выработки оптимальных стратегий развития и совершенствования технологий мобильной связи. Предметом исследования выступили вопросы совершенствования управления экономической эффективностью базовых станций операторов мобильной связи. Экономические отношения операторов мобильной связи, связанные с оценкой организации и управления с учетом современных требований функционирования и развития конкурентного рынка. Проведен подробный анализ рыночной ситуации, методов определения эффективности деятельности операторов мобильной связи. Сформирована единая модель организации и управления. Основное внимание уделено построению алгоритма тестирования, влияющего на организацию и управление объектами инфраструктуры операторов мобильной связи и на успешность оказания качественных услуг связи. Проведен подробный анализ состояния рынка и перспектив его развития. Разработан авторский методический инструментарий организации и управления экономической эффективности на примере базовых станций операторов мобильной связи. Данные исследования будут полезны операторам мобильной связи при оценке конкурентоспособности и формировании эффективных управленческих решений. Кроме того, результаты исследования могут стать основой для дальнейших исследований в области экономики отрасли сотовой связи. Предложены методические положения по управлению ключевыми параметрами, характеризующими услуги мобильной связи в условиях регионального рынка при использовании алгоритма тестирования. Определение этапов управления позволит организациям, предоставляющим услуги мобильной связи, занимать более конкурентоспособное положение и сокращать экономические потери. Предложен алгоритм технико-экономического обоснования для изучения финансовых показателей операторов мобильной связи. Определены два этапа, обеспечивающие экономически эффективное положение операторов мобильной связи: оценка качественного эффекта влияния вида базовых станций на объем дохода операторов мобильной связи и определение типа модели аппроксимации представленных временных рядов. Выбор оптимального метода прогнозирования. Их влияние позволяет определять конкурентный статус и перспективные направления для управления объектов инфраструктурой услуг мобильной связи., The study considers the issues related to improving the cost efficiency management for the infrastructure of mobile operators. We have discussed the economic relations of mobile operators connected with assessment of organization and management taking into account modern requirements of functioning and development of the competitive market. Detailed analysis has been carried out for the market situation and methods of determining the performance efficiency of mobile operators. A uniform model of organization and management has been formed. The main focus is on constructing a testing algorithm influencing the organization and management of infrastructure facilities of mobile operators and the success of rendering good-quality communication services. Detailed analysis of the market’s conditions and the prospects of its development has been carried out. We have developed original methodical tools for organization and management of cost efficiency using the example of base stations of mobile operators. The data of the study should be useful to mobile operators for assessing the competitiveness and making effective management decisions. The results obtained can also become a basis for further studies in economy of cellular communication. We have offered methodological provisions for managing the key parameters characterizing mobile services in the conditions of the regional market when using the testing algorithm. Defining the stages of management could make it possible for the organizations providing mobile service to hold a more competitive position and to reduce economic losses. We have offered an algorithm determining the economic feasibility for studying the financial performance of mobile operators. We have found two stages providing the cost-effective position of mobile operators: stage 1, where the qualitative effect of the type of base stations on the volume of income of mobile operators is assessed, and stage 2, where the model for approximating the given time series is determined and an optimum forecasting method is chosen. The influence depends on the competitive status and the potential directions for management of infrastructure of mobile services.

Published
2019
Full Text
View/download PDF

42. Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma.

Author

Fogt, Sergey, primary, Shustova, Mariia, additional, Demidov, Lev V., additional, Moiseyenko, Vladimir, additional, Tjulandin, Sergei, additional, Semiglazova, Tatiana, additional, Protsenko, Svetlana, additional, Odintsova, Svetlana, additional, Zukov, Ruslan, additional, Lazarev, Sergey, additional, Makarova, Yuliya, additional, Nechaeva, Marina, additional, Sakaeva, Dina, additional, Andreev, Aleksey, additional, Tarasova, Anna, additional, Fadeeva, Natalia, additional, Gavrilova, Olesya, additional, and Ivanov, Roman, additional

Published
2019
Full Text
View/download PDF

43. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Fuchs, Charles S, primary, Shitara, Kohei, additional, Di Bartolomeo, Maria, additional, Lonardi, Sara, additional, Al-Batran, Salah-Eddin, additional, Van Cutsem, Eric, additional, Ilson, David H, additional, Alsina, Maria, additional, Chau, Ian, additional, Lacy, Jill, additional, Ducreux, Michel, additional, Mendez, Guillermo Ariel, additional, Alavez, Alejandro Molina, additional, Takahari, Daisuke, additional, Mansoor, Wasat, additional, Enzinger, Peter C, additional, Gorbounova, Vera, additional, Wainberg, Zev A, additional, Hegewisch-Becker, Susanna, additional, Ferry, David, additional, Lin, Ji, additional, Carlesi, Roberto, additional, Das, Mayukh, additional, Shah, Manish A, additional, Luft, Alexander V., additional, Karaseva, Nina A., additional, Kowalyszyn, Rubén Dario, additional, Hernandez, Carlos Alberto, additional, Csoszi, Tibor, additional, De Vita, Ferdinando, additional, Pfeiffer, Per, additional, Sugimoto, Naotoshi, additional, Kocsis, Judit, additional, Csilla, Andràs, additional, Bodoky, Gyorgy, additional, Garnica Jaliffe, Georgina, additional, Protsenko, Svetlana, additional, Madi, Ayman, additional, Wojcik, Elzbieta, additional, Brenner, Baruch, additional, Folprecht, Gunnar, additional, Sarosiek, Tomasz, additional, Peltola, Katriina Johanna, additional, Bono, Peter, additional, Ayala, Hubert, additional, Aprile, Giuseppe, additional, Gerardo, Cardellino Giovanni, additional, Huitzil Melendez, Fidel David, additional, Falcone, Alfredo, additional, Di Costanzo, Francesco, additional, Tehfe, Moustapha, additional, Mineur, Laurent, additional, García Alfonso, Pilar, additional, Obermannova, Radka, additional, Senellart, Hélène, additional, Petty, Russell, additional, Samuel, Leslie, additional, Acs, Peter Istvan, additional, Hussein, Maen Abdelkarim, additional, Nechaeva, Marina N., additional, Erdkamp, F.L.G., additional, Won, Elizabeth, additional, Bendell, Johanna Chock, additional, Gallego Plazas, Javier, additional, Lorenzen, Sylvie, additional, Melichar, Bohuslav, additional, Escudero, Miguel Angel, additional, Pezet, Denis, additional, Phelip, Jean-Marc, additional, Kaen, Diego Lucas, additional, Reeves, James A. Jr, additional, Longo Muñoz, Federico, additional, Madhusudan, Srinivasan, additional, Barone, Carlo, additional, Fein, Luis Enrique, additional, Gomez Villanueva, Angel, additional, Hebbar, Mohamed, additional, Prausova, Jana, additional, Visa Turmo, Laura, additional, Vidal Barrull, Joana, additional, Yilmaz, Mette Karen Nytoft, additional, Beny, Alex, additional, Van Laarhoven, H.M.W., additional, DiCarlo, Brian Anthony, additional, Esaki, Taito, additional, Fujitani, Kazumasa, additional, Geboes, Karen, additional, Geva, Ravit, additional, Kadowaki, Shigenori, additional, Leong, Stephen, additional, Machida, Nozomu, additional, Raj, Moses Sundar, additional, Ramirez Godinez, Francisco Javier, additional, Ruzsa, Agnes, additional, Ford, Hugo, additional, Lawler, William E., additional, Maisey, Nicolas Robert, additional, Petera, Jiri, additional, Shacham-Shmueli, Einat, additional, Sinapi, Isabelle, additional, Yamaguchi, Kensei, additional, Hara, Hiroki, additional, Beck, Joseph Thaddeus, additional, Błasińska-Morawiec, Maria, additional, Villalobos Valencia, Ricardo, additional, Alcindor, Thierry, additional, Bajaj, Madhuri, additional, Berry, Scott, additional, Gomez, Christina Maria, additional, Dammrich, Daniel, additional, Patel, Ravindranath, additional, Taieb, Julien, additional, Ten Tije, A.J., additional, Burkes, Ronald L., additional, Cabanillas, Fernando, additional, Firdaus, Irfan, additional, Chua, Cynthia Coo, additional, Hironaka, Shuichi, additional, Hofheinz, Ralf-Dieter, additional, Lim, Howard J., additional, Nordsmark, Marianne, additional, Piko, Bela, additional, Verma, Udit, additional, Wadsley, Jonathan, additional, Yukisawa, Seigo, additional, Gutiérrez Delgado, Francisco, additional, Denlinger, Crystal S., additional, Kallio, Raija, additional, Pikiel, Joanna, additional, Wojcik-Tomaszewska, Joanna, additional, Brezden-Masley, Christine, additional, Jang, Raymond Woo-Jun, additional, Pribylova, Jana, additional, Sakai, Daisuke, additional, Bartoli, Maria Alejandra, additional, Cats, A., additional, Grootscholten, M.I., additional, Dichmann, Robert Andrew, additional, Hool, Hugo, additional, Shaib, Walid, additional, Tsuji, Akihito, additional, Van den Eynde, Marc, additional, Velez-Cortez, Hector, additional, and Asmis, Timothy R., additional

Published
2019
Full Text
View/download PDF

44. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Author

Gorbunova, Vera, primary, Beck, J. Thaddeus, additional, Hofheinz, Ralf-Dieter, additional, Garcia-Alfonso, Pilar, additional, Nechaeva, Marina, additional, Cubillo Gracian, Antonio, additional, Mangel, Laszlo, additional, Elez Fernandez, Elena, additional, Deming, Dustin A., additional, Ramanathan, Ramesh K., additional, Torres, Alison H., additional, Sullivan, Danielle, additional, Luo, Yan, additional, and Berlin, Jordan D., additional

Published
2018
Full Text
View/download PDF

45. Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Author

Gorbunova, Vera, primary, Beck, Thaddeus, additional, Hofheinz, Ralf, additional, Garcia-Alfonso, Pilar, additional, Nechaeva, Marina, additional, Cubillo Gracian, Antonio, additional, Mangel, Laszlo, additional, Elez, Elena, additional, Deming, Dustin A., additional, Ramanathan, Ramesh K., additional, Torres, Alison, additional, Sullivan, Danielle Marie, additional, Komarnitsky, Philip B., additional, and Berlin, Jordan, additional

Published
2018
Full Text
View/download PDF

47. FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Author

Al-Batran, Salah-Eddin, primary, Schuler, Martin H., additional, Zvirbule, Zanete, additional, Manikhas, Georgiy, additional, Lordick, Florian, additional, Rusyn, Andriy, additional, Vynnyk, Yuriy, additional, Vynnychenko, Ihor, additional, Fadeeva, Natalia, additional, Nechaeva, Marina, additional, Dudov, Assen, additional, Gotovkin, Evgeny, additional, Pecheniy, Alexander, additional, Bazin, Igor, additional, Bondarenko, Igor, additional, Melichar, Bohuslav, additional, Mueller, Christian, additional, Huber, Christoph, additional, Tureci, Oezlem, additional, and Sahin, Ugur, additional

Published
2016
Full Text
View/download PDF

48. Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.

Author

Fogt, Sergey, Andabekov, Timur, Shamsutdinova, Yana, Dvorkin, Mikhail, Artamonova, Elena, Chistyakov, Valerii, Zukov, Ruslan, Moiseenko, Vladimir, Nechaeva, Marina, Odintsova, Svetlana, Fadeeva, Natalia, Kislov, Nikolai, Tantsyrev, Denis, Tjulandin, Sergei, Fomin, Eugeniy, Linkova, Iuliia, Zinkina-Orikhan, Arina, Shustova, Mariia, and Zhukova, Lyudmila

Published
2023
Full Text
View/download PDF

49. Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.

Author

Filon, Olga, primary, Nechaeva, Marina, additional, Burdaeva, Olga, additional, Vladimirov, Vladimir Ivanovich, additional, Lifirenko, Igor, additional, Kovalenko, Nadezhda Vitalievna, additional, Kopp, Mikhail V., additional, Matrosova, Marina, additional, Mukhametsina, Guzel, additional, Panchenko, Sergey, additional, Skopin, Pavel, additional, Stroyakovskiy, Daniil, additional, Krivorotko, Petr, additional, Shapovalova, Julia, additional, Jelvakova, Irina, additional, Sheveleva, Ludmila, additional, Abrosimova, Anastasia, additional, Ivanov, Roman, additional, and Tjulandin, Sergei, additional

Published
2015
Full Text
View/download PDF

50. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.

Author

Stenina, Marina B., primary, Ignatova, Ekaterina, additional, Frolova, Mona A., additional, Burdaeva, Olga N., additional, Nechaeva, Marina P., additional, Kopp, Mikhail V., additional, Udovitsa, Dmitry P., additional, Kotiv, Bogdan N., additional, Alekseev, Sergiy M., additional, Stroyakovsky, Daniil L., additional, Sheveleva, Ludmila P., additional, Khorinko, Andrey V., additional, Prokopenko, Tatiana I., additional, Shapovalova, Julia S., additional, Jelvakova, Irina A., additional, Ivanov, R., additional, Filon, Olga V., additional, and Tjulandin, Sergei, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results